Divalproex Sodium Capsule, Coated Pellets
Product Images NDC 27241-115

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 27241-115). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex-125mg (Divalproex 125mg)

Label for Divalproex Sodium 125 mg delayed-release capsules, USP, sprinkled form, containing coated pellets. Bottle label indicates 100 capsules packaged by Ajanta Pharma USA Inc., Bridgewater, NJ. Label includes dosing advisory, storage instructions, child resistance warning, and a capsule image marked DV 125. The label also shows barcode and mentions the product is made in India.*

FDA Label Image

Figure3 (Divalproex Fig3)

Divalproex sodium 125 mg coated pellets capsule, oral dosage form. The capsule is marked with 'DV' and '125' indicating the strength. The product is labeled by Ajanta Pharma USA Inc.*

FDA Label Image

Figure4 (Divalproex Fig4)

Divalproex sodium 125 mg coated pellets capsule with imprint 'DV' on one side and '125' on the other, designed for oral administration. The capsule is primarily white with a greyish section. Manufactured by Ajanta Pharma USA Inc.*

FDA Label Image

Figure5 (Divalproex Fig5)

Divalproex sodium 125 mg capsules, coated pellets, by Ajanta Pharma USA Inc., shown with capsules open and pellets spilling out, for oral administration.*

FDA Label Image

Figure6 (Divalproex Fig6)

An black and white photograph illustration of a young child about to take medicine from a spoon, highlighting the oral route of administration relevant to pediatric medication.*

FDA Label Image

Figure1 (Divalproex Figure1)

A cumulative response curve graph comparing the percentage reduction in CPS (clinical parameter score) rate between Divalproex sodium and placebo. The graph plots percent of patients on the x-axis against percentage reduction in CPS rate on the y-axis, indicating patient improvement or worsening with labeled solid line for Divalproex sodium and dashed line for placebo.*

FDA Label Image

Figure2 (Divalproex Figure2)

A cumulative distribution graph showing the percentage reduction in CPS rate among patients at high and low doses of Divalproex sodium capsules. The X-axis represents the percentage of patients from 0 to 100, and the Y-axis shows the percentage reduction in CPS rate from -100% (worsening) to 100% (improvement). Two curves compare outcomes for high dose (solid line) and low dose (dashed line).*

FDA Label Image

Structure (Divalproex Structure)

Chemical structure of divalproex sodium, depicting the sodium salt form with two valproate molecules coordinated to a sodium ion, represented with carbon chains and functional groups enclosed in a polymeric notation (n).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.